|
|
|
In this report
September added one approved AAV therapy while editor engineering widened the technical envelope, and regulation became more concrete in both agriculture and heritable editing.
- FDA approved Ultragenyx's FAYUVI, the first treatment for pediatric MPS IIIA.
- Patient-derived HSPCs reached up to 70% prime-editing efficiency for a GATA2 variant.
- EU rules now distinguish Category 1 and Category 2 new genomic techniques.
Contents
|
|
Clinical translation and editor performance
|
FDA approves Ultragenyx's FAYUVI for MPS IIIAGene therapy clinical trials and approvals
FDA approval gives children with MPS IIIA an AAV9 SGSH gene-replacement option where no treatment previously existed, moving this ultrarare disease from experimental therapy into clinical administration.
- FAYUVI is delivered by intravenous infusion and was developed through the Nationwide Children's gene-therapy programme, with Andelyn Biosciences as commercial manufacturer.
- The disease affects about 1 in 70,000 live births; the first trial participant received treatment in 2016, and Nationwide Children's will be a qualified treatment centre.
What this means for you The clinical gene-editing landscape now sits alongside another approved pediatric AAV therapy, making durability, access and administration infrastructure increasingly central comparators for translational programmes. |
|
Prime editing corrects GATA2 variants in patient HSPCsGene therapy clinical trials and approvals
Patient-derived blood stem cells carrying a GATA2 deficiency variant reached up to 70% prime-editing efficiency, an ex vivo result that strengthens the case for editing approaches designed to preserve stem-cell function.
- Editing increased functional GATA2 alleles from 50% to 77%, and edited cells showed greater engraftment potential than untreated cells.
- The study detected limited on-target genotoxicity and no off-target editing at its top 20 predicted sites; PASSIGE extended the approach towards site-specific cDNA insertion without a double-strand break.
What this means for you For ex vivo hematopoietic editing, efficiency is no longer the only translational readout: preservation of stemness, engraftment and genotoxicity controls are part of the result itself. |
|
Engineers make CgCas12n 60 times more efficientNew editors and editing techniques
Arginine enrichment raised the compact CgCas12n nuclease's editing efficiency about 60-fold in mammalian cells, pairing a smaller editor with a more usable performance profile.
- Guide-scaffold optimisation shortened the RNA by 38 bases, while the engineered base editor supported C-to-T conversion across positions 2 to 17.
- AAV9 delivery produced editing in mouse skeletal muscle, with minimal transcriptome- and genome-level off-target editing detected in the reported assays.
What this means for you Compactness and activity are becoming co-optimisable properties for AAV editing systems, although the evidence remains a mammalian-cell and mouse demonstration rather than a therapeutic result. |
|
Researchers build hypercompact xCas12m epigenome editorNew editors and editing techniques
Structure-guided engineering produced xCas12m, a compact, non-cleaving epigenome editor that achieved durable silencing from a single AAV vector in a mouse hepatitis B model.
- The parent PmCas12m recognises a flexible 5′-YTN-3′ PAM and binds double-stranded DNA without cutting it.
- xCas12m was combined with CRISPRoff and showed potent, specific epigenetic repression in human cells before in vivo testing.
What this means for you AAV payload limits can now be addressed alongside editing chemistry in epigenome applications, but durability and tissue-level performance remain preclinical questions. |
|
Un1Cas12f1 restores dystrophin in DMD miceGene therapy clinical trials and approvals
A compact Un1Cas12f1 system used multiplexed exon excision to restore dystrophin expression in a mouse DMD model, addressing the multi-cut requirement of large-gene reading-frame repair.
- The nuclease tolerated several non-canonical PAMs, including Y-rich motifs, expanding its targetable sequence range.
- A single transcript carried guides for as many as five loci, and an all-in-one AAV restored the Dmd open reading frame after intramuscular delivery.
What this means for you For therapeutic exon skipping, compact multiplexed architectures can relax both PAM and packaging constraints, while the result still stops at mouse-level evidence. |
|
Delivery, safety and governance |
Embryo study exposes base-editing safety limitsDelivery and safety
Base editing reached all PCSK9 alleles in a human-embryo study without detected indels, but chromosome breakage, mosaic effects and delivery-dependent embryo arrest keep reproductive use out of reach.
- Protein delivery supported development to the blastocyst stage and enabled homozygous edited stem-cell lines, while rare on-target chromosome abnormalities still occurred.
- mRNA delivery caused frequent embryo arrest, attributed to guide-independent deaminase activity; bystander and off-target effects were mosaic.
What this means for you Delivery format is itself a safety variable in developmental editing, and efficient intended editing cannot be separated from genome integrity and developmental outcomes. |
|
Japan criminalizes implantation of edited embryosRegulation, patents and companies
Japan's Act No. 70 of 2026 replaced non-binding guidance with a penalized prohibition on implanting heritable genome-edited embryos, closing a specific enforcement gap.
- The law addresses a gap left by earlier cloning legislation, which criminalised implantation of cloned embryos but did not expressly cover genome-edited embryos.
- The scope is national, and comparative analysis notes that prohibitions differ in coverage and can be bypassed by seeking procedures elsewhere.
What this means for you Governance of heritable editing is gaining enforceable national precedents, but the regulatory landscape remains uneven rather than globally harmonised. |
|
Agricultural editing and implementation |
EU creates two pathways for gene-edited cropsGene editing in agriculture
Regulation 2026/1388 creates Category 1 and Category 2 routes for plants made with targeted mutagenesis or cisgenesis, although most provisions will not apply until July 2028.
- Category 1 covers defined changes, including substitutions or insertions of up to 20 nucleotides and deletions, subject to limits on the number of changes and excluded traits.
- Category 2 remains under GMO risk assessment, traceability and labelling rules; Category 1 seed must carry an NGT-1 label and NGT plants remain excluded from organic production.
What this means for you EU agricultural editing now has a statutory route that distinguishes product categories, but verification, labelling and implementation are still future operating constraints. |
|
CAS combines knockout and genome restructuring in riceGene editing in agriculture
Chinese Academy of Sciences researchers combined deterministic knockout, precise editing and kilobase-scale genome restructuring in rice through the TKO and TRIM systems.
- TKO averaged 96.8% single-gene knockout efficiency in regenerated T0 plants and supported simultaneous knockout of up to 10 genes with orthogonal systems.
- TRIM2 reported 22.8% composite efficiency for one knockout plus precise editing of three genes, alongside insertion, replacement, deletion, inversion and translocation capabilities.
What this means for you Crop editing platforms are converging on multi-function trait engineering rather than single-locus modification, but the reported evidence is still confined to rice plants and early generations. |
|
How Iris covered your topics this month Every topic you track was searched over the last month. | Topic | Sources found | In this briefing | | New editors and editing techniques | 18 | 2 stories | | Gene therapy clinical trials and approvals | 20 | 3 stories | | Delivery and safety | 17 | 1 story | | Gene editing in agriculture | 11 | 2 stories | | Regulation, patents and companies | 14 | 1 story |
|
